| Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979) |
|---|
| 02/18/2010 | CA2733646A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | CA2733397A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/17/2010 | EP2154135A1 Therapeutic agent for cerebral infarction |
| 02/17/2010 | EP2154130A1 Pyridone compound |
| 02/17/2010 | EP2153832A2 Heterocyclic aspartyl protease inhibitors |
| 02/17/2010 | EP2152710A2 4,4-disubstituted piperidine derivatives |
| 02/17/2010 | EP2152701A1 Phenyl amino pyrimidine compounds and uses thereof |
| 02/17/2010 | EP2152694A2 Thiazoles and pyrazoles useful as kinase inhibitors |
| 02/17/2010 | EP2152693A1 2-morpholin-4-yl-pyrimidines as pi3k inhibitors |
| 02/17/2010 | EP2152691A1 An improved process for preparing an optically active proton pump inhibitor |
| 02/17/2010 | EP2152690A1 Pyridyl piperidine orexin receptor antagonists |
| 02/17/2010 | EP2152689A1 Analogues of cilostazol |
| 02/17/2010 | EP2152688A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 02/17/2010 | EP2152674A1 Benzimidazolone chymase inhibitors |
| 02/17/2010 | EP2152672A1 Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| 02/17/2010 | EP2152671A1 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |
| 02/17/2010 | EP2152664A1 Dipeptide analogs as coagulation factor inhibitors |
| 02/17/2010 | EP2152370A1 Aryl ether pyridazinone derivatives |
| 02/17/2010 | EP2152080A1 Novel soluble 1,4 benzodiazepine compounds and stable salts thereof |
| 02/17/2010 | EP2152079A1 Heterocyclic compounds and uses thereof |
| 02/17/2010 | EP2091942B1 Substituted pyrazinone derivatives for use as a medicine |
| 02/17/2010 | EP1979321B9 Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |
| 02/17/2010 | EP1902026B1 Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm) |
| 02/17/2010 | EP1758888B1 Butyrylcholinesterase selective inhibitors |
| 02/17/2010 | EP1729818B8 Contrast agents for magnetic resonance imaging |
| 02/17/2010 | EP1549318B1 Crystal structure of aurora-2 protein and binding pockets thereof |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | CN101652358A Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same |
| 02/17/2010 | CN101652357A Method for producing quinolone carboxylic acid derivative |
| 02/17/2010 | CN101648947A 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| 02/17/2010 | CN101648944A 病毒聚合酶抑制剂 Viral polymerase inhibitors |
| 02/17/2010 | CN101648943A Method for preparing (S)-omeprazole in subject and object after inclusion and resolution by separation |
| 02/17/2010 | CN101648942A Method for preparing halofuginone derivative |
| 02/17/2010 | CN101648941A 4-tetrazolyl-4phenylpiperidine derivatives for treating pain |
| 02/17/2010 | CN100590118C Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor |
| 02/16/2010 | US7662968 Process for preparing lansoprazole |
| 02/16/2010 | US7662966 For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions |
| 02/16/2010 | US7662961 5,5'-{Oxybis[ethane-2,1-diyl(methylimino)]}bis[1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonylpyrazole]; pest control of insects, arachnids and helminths |
| 02/16/2010 | US7662956 Ethyl[7-chloro-5-(2-chloroprene)-1-isobutyl-2-oxo-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-acetate; dyslipidaemia, arteriosclerosis, restenosis and ischemia |
| 02/16/2010 | US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 |
| 02/16/2010 | US7662839 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid |
| 02/16/2010 | US7662838 containing N-(5-adamantane-1-yl-methoxy-pentyl)- group; for treatment of insulin resistance, hyperpigmentation and/or inflammatory processes in skin, fungal disease, overweight and obesity, or microbacterial infection |
| 02/16/2010 | US7662837 Inhibitors of c-fms kinase |
| 02/16/2010 | US7662834 Methods of 1H-indol-3-yl-2-oxoacetamide compounds |
| 02/16/2010 | US7662830 2-{4-[6-(3-Chloro-4-fluoro-phenyl)-2-morpholin-4-yl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid ethyl ester; 5-Methyl-6-{4-[2-(2-methyl-pyrrolidin-1-yl)-6-phenyl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid; treating conditions related to capsaicin receptor activation; neurophathic pain |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662818 e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis |
| 02/16/2010 | US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome |
| 02/16/2010 | US7662816 Cognition activators; neurodegenerative disorders; Alzheimer's disease |
| 02/16/2010 | US7662813 Triazole compounds that modulate HSP90 activity |
| 02/16/2010 | US7662811 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use |
| 02/16/2010 | CA2575003C Potassium channel inhibitors |
| 02/16/2010 | CA2571627C Substituted aryl-amine derivatives and methods of use |
| 02/16/2010 | CA2478183C Substituted amides |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/16/2010 | CA2407043C Naphthamidine urokinase inhibitors |
| 02/16/2010 | CA2402748C Method of producing 6-substituted (s)-nicotine derivatives and intermediate compounds |
| 02/16/2010 | CA2385938C Cyclic amine compounds as ccr5 antagonists |
| 02/16/2010 | CA2385081C Carboxylic acid compound and a medicament comprising it |
| 02/11/2010 | WO2010017545A2 Triazole compounds that modulate hsp90 activity |
| 02/11/2010 | WO2010017401A1 Bi-1h-benzimidazoles as hepatitis c virus inhibitors |
| 02/11/2010 | WO2010017350A1 Aminopyridine kinase inhibitors |
| 02/11/2010 | WO2010017240A2 Aurora kinase modulators and methods of use |
| 02/11/2010 | WO2010016554A1 Cyclic amine compound |
| 02/11/2010 | WO2010016552A1 Therapeutic agent for irritable bowel syndrome |
| 02/11/2010 | WO2010016005A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 02/11/2010 | WO2010015972A1 Diazepine and diazocane compounds as mc4 agonists |
| 02/11/2010 | WO2010015681A1 Fungicidal n-(2-pyridylpropyl)carboxamide derivatives and their oxa, aza and thia analogues |
| 02/11/2010 | WO2010015675A1 Process for the preparation of nicotine-based haptens |
| 02/11/2010 | WO2010015653A1 Pyrimidine derivatives as activators of soluble guanylate cyclase |
| 02/11/2010 | WO2009141532A3 Derivatives of 1,5-diphenyl pyrrole-3-carboxamide, preparation thereof and use of same as cannabinoid cb1 receptor antagonists |
| 02/11/2010 | US20100036136 Maleimide Containing Ester and Sulfide Functionalities |
| 02/11/2010 | US20100036125 Synthesis of ccr5 receptor antagonists |
| 02/11/2010 | US20100036118 Fused Ring Heterocycle Kinase Modulators |
| 02/11/2010 | US20100036117 Pyrimidine compound and pests controlling composition containing the same |
| 02/11/2010 | US20100036102 Novel chelating agents and highly luminescent and stable chelates and their use |
| 02/11/2010 | US20100035935 Anthranilamide compounds, process for their production and pesticides containing them |
| 02/11/2010 | US20100035934 Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| 02/11/2010 | US20100035931 Tripyridyl carboxamide orexin receptor antagonists |
| 02/11/2010 | US20100035929 Unnatural dispyrin analogues, preparation and uses thereof |
| 02/11/2010 | US20100035926 Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands |
| 02/11/2010 | US20100035907 New 2,4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors |
| 02/11/2010 | US20100035906 Dipyridyl-dihydropyrazolones and their use |
| 02/11/2010 | US20100035903 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases |
| 02/11/2010 | US20100035898 Organic compounds |
| 02/11/2010 | US20100035897 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists |
| 02/11/2010 | US20100035895 2-aminocarbonyl-pyridine derivatives |
| 02/11/2010 | US20100035891 Pharmaceutically Active Compounds |
| 02/11/2010 | US20100035880 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists |
| 02/11/2010 | US20100035873 Diaryl Compounds and Uses Thereof |
| 02/11/2010 | US20100035869 Targeted nitroxide agents |
| 02/11/2010 | US20100035862 Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| 02/11/2010 | US20100035826 Controlled release of phenolic opioids |
| 02/11/2010 | US20100035279 Fluorescent Substrates for Monoamine Transporters as Optical False Neurotransmitters |
| 02/11/2010 | US20100034827 Novel hiv reverse transcriptase inhibitors |
| 02/11/2010 | US20100034813 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 02/11/2010 | US20100032658 Novel organic electroluminescent compounds and organic electroluminescent device using the same |
| 02/11/2010 | CA2732765A1 Aminopyridine kinase inhibitors |
| 02/11/2010 | CA2732101A1 Aurora kinase modulators and methods of use |